Demographic features of adult ITP patients
| Study . | No. of patients . | Male/female . | No. of infected patients (%) . | Age of infected patients, y . | Age of uninfected patients, y . | Platelet count of infected patients, ×109/L . | Platelet count of uninfected patients, ×109/L . | ITP duration, mo . | Concomitant therapy . | Untreated/splenectomized patients . |
|---|---|---|---|---|---|---|---|---|---|---|
| Gasbarrini et al (1998)2 | 18 | 5/13 | 11 (61) | 43 ± 14 | 49 ± 12 | 95 ± 39 | 103 ± 24 | NR | NR | <NR |
| Jarque et al (2001)18 | 56 | 18/38 | 40 (71) | 54 (17–80)* | 57 ± 22† | 58 ± 23 | 32 (2–50) | 0/56 | 39/4 | |
| Kohda et al (2002)19 | 40 | 12/28 | 25 (62) | 54 ± 14 | 48 ± 13 | 67 ± 54 | 60 ± 41 | 41 ± 38 | 19/40 | 13/NR |
| Hino et al (2003)20 | 30 | 8/22 | 21 (70) | 55 ± 15 | 51 ± 17 | 38 ± 20 | 22 ± 12 | NR | 7/30 | 15/1 |
| Hashino et al (2003)21 | 22 | 9/13 | 14 (64) | 53.2 ± 12.9 | 41.8 ± 18.6 | 61 ± 26 | 63 ± 20 | 110 ± 81 | 8/22 | 8/2 |
| Ando et al (2003)22 | 61 | 12/49 | 50 (82) | 58 ± 11 | 40 ± 16 | 56 ± 24 | 42 ± 24 | 78 ± 65 | NR | 38/NR |
| Michel et al (2004)23 | 74 | 21/53 | 16 (22) | 52.5 ± 15.9 | 38.5 ± 18.3 | 32 ± 15 | 26 ± 17‡ | 10.2 y | 9/25 | 0/NR |
| Takahashi et al (2004)24 | 20 | 5/15 | 15 (75) | 54 ± 13 | 46 ± 18 | 40 ± 27 | 39 ± 22 | 51 ± 15 | NR | 7/13 |
| Sato et al (2004)25 | 53 | 16/37 | 39 (74) | 62 (37–87)§ | 52 (39–77)§ | 54 ± 17 | 59 ± 22 | 59 (6–624)§ | 27/53 | NR |
| Ando et al (2004)26 | 20 | 5/15 | 17 (85) | 62 (38–83)‖ | 48 (4–86) | 41 (12–82) | NR | NR | NR | |
| Nomura et al (2004)27 | 42 | 15/27 | 28 (66) | NR | NR | 29 ± 6 | 31 ± 5 | NR | NR | 21/21 |
| Veneri et al (2005)28 | 52 | 23/29 | 34 (65) | 57 (24–72)¶ | NR | 57 ± 23 | NR | NR | NR | 34/6 |
| Inaba et al (2005)29 | 35 | 11/24 | 25 (71) | 57 (25–82)* | 52 ± 26 | 40 | 0/35 | 8/27 | ||
| Stasi et al (2005)30 | 137 | 57/80 | 64 (47) | 58 ± 13 | 42 ± 16 | 42 ± 25 | 46 ± 23 | 25 ± 19 | 16/137 | 67/10 |
| Fujimura et al (2005)39 | 435 | 120/315 | 300 (69) | 59 ± 14 | 47 ± 16 | NA | NA | 8.2 ± 6.8 y | NR | 133/70 |
| Suzuki et al (2005)17 | 36 | NR | 25 (69) | NR | NR | 55 ± 27 | NR | NR | NR | NR |
| Suvajdzić et al (2006)31 | 54 | 12/42 | 39 (72) | 54 ± 13 | 42 ± 16 | 68 ± 32 | 78 ± 32 | 6 (1–30) y | 0/54 | NR |
| Ahn et al (2006)32 | 15 | 5/10 | 15 (100)# | 56.8 ± 18.5 | NA | 72 ± 45 | NA | 104.4 ± 79.2 | 11/15 | 0/5 |
| Sayan et al (2006)33 | 34 | 22/12 | 20 (59) | 50.8 ± 16.2 | 53.8 ± 17.6 | 37 ± 16 | 39 ± 16 | 19 ± 15 | NR | NR |
| Asahi et al (2006)34 | 37 | 14/23 | 26 (70) | NR | NR | NR | NR | NR | NR | NR |
| Kodama et al (2007)35 | 116 | 32/74 | 67 (58) | 57.9 ± 14.3 | 47.8 ± 17.2 | 39 ± 29 | 30 ± 24 | NA | NA | NA |
| Campuzano-Maya (2007)40 | 32 | 7/25 | 29 (91) | NR | NR | 57 ± 38 | NR | NR | NR | NR |
| Estrada-Gómez et al (2007)36 | 23 | NR | 14 (61) | NR | NR | NR | NR | NR | NR | NR |
| Satake et al (2007)37 | 38 | 9/29 | 12 (68) | NR | NR | NR | NR | NR | NR | 19/8 |
| Emilia et al (2007)38 | 75 | 36/39 | 38 (51) | 58 ± 19 | 49.9 ± 20.7 | 41 ± 24 | 28 ± 18 | 24.4 ± 30.1 | 24/75 | 36/4 |
| Study . | No. of patients . | Male/female . | No. of infected patients (%) . | Age of infected patients, y . | Age of uninfected patients, y . | Platelet count of infected patients, ×109/L . | Platelet count of uninfected patients, ×109/L . | ITP duration, mo . | Concomitant therapy . | Untreated/splenectomized patients . |
|---|---|---|---|---|---|---|---|---|---|---|
| Gasbarrini et al (1998)2 | 18 | 5/13 | 11 (61) | 43 ± 14 | 49 ± 12 | 95 ± 39 | 103 ± 24 | NR | NR | <NR |
| Jarque et al (2001)18 | 56 | 18/38 | 40 (71) | 54 (17–80)* | 57 ± 22† | 58 ± 23 | 32 (2–50) | 0/56 | 39/4 | |
| Kohda et al (2002)19 | 40 | 12/28 | 25 (62) | 54 ± 14 | 48 ± 13 | 67 ± 54 | 60 ± 41 | 41 ± 38 | 19/40 | 13/NR |
| Hino et al (2003)20 | 30 | 8/22 | 21 (70) | 55 ± 15 | 51 ± 17 | 38 ± 20 | 22 ± 12 | NR | 7/30 | 15/1 |
| Hashino et al (2003)21 | 22 | 9/13 | 14 (64) | 53.2 ± 12.9 | 41.8 ± 18.6 | 61 ± 26 | 63 ± 20 | 110 ± 81 | 8/22 | 8/2 |
| Ando et al (2003)22 | 61 | 12/49 | 50 (82) | 58 ± 11 | 40 ± 16 | 56 ± 24 | 42 ± 24 | 78 ± 65 | NR | 38/NR |
| Michel et al (2004)23 | 74 | 21/53 | 16 (22) | 52.5 ± 15.9 | 38.5 ± 18.3 | 32 ± 15 | 26 ± 17‡ | 10.2 y | 9/25 | 0/NR |
| Takahashi et al (2004)24 | 20 | 5/15 | 15 (75) | 54 ± 13 | 46 ± 18 | 40 ± 27 | 39 ± 22 | 51 ± 15 | NR | 7/13 |
| Sato et al (2004)25 | 53 | 16/37 | 39 (74) | 62 (37–87)§ | 52 (39–77)§ | 54 ± 17 | 59 ± 22 | 59 (6–624)§ | 27/53 | NR |
| Ando et al (2004)26 | 20 | 5/15 | 17 (85) | 62 (38–83)‖ | 48 (4–86) | 41 (12–82) | NR | NR | NR | |
| Nomura et al (2004)27 | 42 | 15/27 | 28 (66) | NR | NR | 29 ± 6 | 31 ± 5 | NR | NR | 21/21 |
| Veneri et al (2005)28 | 52 | 23/29 | 34 (65) | 57 (24–72)¶ | NR | 57 ± 23 | NR | NR | NR | 34/6 |
| Inaba et al (2005)29 | 35 | 11/24 | 25 (71) | 57 (25–82)* | 52 ± 26 | 40 | 0/35 | 8/27 | ||
| Stasi et al (2005)30 | 137 | 57/80 | 64 (47) | 58 ± 13 | 42 ± 16 | 42 ± 25 | 46 ± 23 | 25 ± 19 | 16/137 | 67/10 |
| Fujimura et al (2005)39 | 435 | 120/315 | 300 (69) | 59 ± 14 | 47 ± 16 | NA | NA | 8.2 ± 6.8 y | NR | 133/70 |
| Suzuki et al (2005)17 | 36 | NR | 25 (69) | NR | NR | 55 ± 27 | NR | NR | NR | NR |
| Suvajdzić et al (2006)31 | 54 | 12/42 | 39 (72) | 54 ± 13 | 42 ± 16 | 68 ± 32 | 78 ± 32 | 6 (1–30) y | 0/54 | NR |
| Ahn et al (2006)32 | 15 | 5/10 | 15 (100)# | 56.8 ± 18.5 | NA | 72 ± 45 | NA | 104.4 ± 79.2 | 11/15 | 0/5 |
| Sayan et al (2006)33 | 34 | 22/12 | 20 (59) | 50.8 ± 16.2 | 53.8 ± 17.6 | 37 ± 16 | 39 ± 16 | 19 ± 15 | NR | NR |
| Asahi et al (2006)34 | 37 | 14/23 | 26 (70) | NR | NR | NR | NR | NR | NR | NR |
| Kodama et al (2007)35 | 116 | 32/74 | 67 (58) | 57.9 ± 14.3 | 47.8 ± 17.2 | 39 ± 29 | 30 ± 24 | NA | NA | NA |
| Campuzano-Maya (2007)40 | 32 | 7/25 | 29 (91) | NR | NR | 57 ± 38 | NR | NR | NR | NR |
| Estrada-Gómez et al (2007)36 | 23 | NR | 14 (61) | NR | NR | NR | NR | NR | NR | NR |
| Satake et al (2007)37 | 38 | 9/29 | 12 (68) | NR | NR | NR | NR | NR | NR | 19/8 |
| Emilia et al (2007)38 | 75 | 36/39 | 38 (51) | 58 ± 19 | 49.9 ± 20.7 | 41 ± 24 | 28 ± 18 | 24.4 ± 30.1 | 24/75 | 36/4 |
Results are given as mean plus or minus standard deviation, or as median (range), unless otherwise noted.
NR indicates not reported; and NA, not assessable.
Age of all patients.
Values of 23 patients who underwent eradication therapy.
H pylori–negative patients who underwent eradication therapy.
Mean (range).
Platelet count of all patients.
Median values (range).
This series included only infected patients.